SP is obviously important to a growth stock but I was pointing out that there are strong indications there is strong upside risk so the SP will follow at some point. They have certainly set off in the right direction and if sales are even half as good in terms of increase next year then SP will jump like a cat sniffing a pickle (look it up). That is likely given the market opportunities as noted.
As with all biomedical companies, patience is required to get in and out with a profit but my experience is that if the fundamentals are sound and the business case is strong then the reward is sufficient for the wait.
IMHO and DYOR.
AT1 FY21 - General Discussion + FA, page-614
-
- There are more pages in this discussion • 1,820 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.06M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 664492 | 2.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 7674 | 2 |
View Market Depth
| Last trade - 16.12pm 16/10/2024 (20 minute delay) ? |
| AT1 (ASX) Chart |
Day chart unavailable